Macimorelin: A Literature Course in Six Modules

Macimorelin is an orally administered ghrelin receptor agonist that appears in the published literature mainly as a growth hormone (GH) stimulation agent used for the diagnosis of adult growth hormone deficiency (AGHD), with smaller bodies of work in childhood-onset GH deficiency, cancer cachexia, seizure models, cardiac safety pharmacology and receptor structural biology. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Nothing below is a protocol, a recommendation, or a prediction of any individual outcome.

The course runs in six modules. Module 1 covers what macimorelin is and how it has been studied; Module 2 covers mechanism as described in the literature; Module 3 summarises reported outcomes study by study; Module 4 covers adverse events as published; Module 5 covers pharmacokinetics where data exist; Module 6 covers regulatory status. Each module ends with a short statement of the limits of the evidence, and the page closes with what the studies did not test.

Module 1: What macimorelin is and how it has been studied

Definition and class

Macimorelin is described in the diagnostic literature as an orally active, small-molecule peptidomimetic agonist of the growth hormone secretagogue receptor (GHSR-1a), the receptor for the endogenous hormone ghrelin; it was developed as an oral alternative to injected or infused GH stimulation agents for testing the somatotroph axis (PMID 24834478). Compounds in this class are collectively called growth hormone secretagogues, and macimorelin is grouped with them in structural pharmacology work that examined how the receptor recognises both macimorelin and the related agonist anamorelin (PMID 40542284).

Origin and development identifier

Macimorelin was carried through clinical development under the code AEZS-130, and the pivotal oral stimulation test bearing that identifier was published as a validation study in adults evaluated for GH deficiency (PMID 23559086). Later literature refers to the compound as macimorelin acetate, the salt form used in the approved diagnostic product discussed in a review of childhood-onset GH deficiency testing (PMID 36694890).

Forms studied

Across the clinical literature macimorelin has been studied as an oral formulation reconstituted in water and dosed by body weight, with 0.5 mg/kg used as the oral test dose in the validation study (PMID 23559086) and in the randomized comparison against the insulin tolerance test (PMID 29860473). Injectable macimorelin does not feature in this verified literature; the oral route is the defining feature of the agent as studied.

How it has been studied

The study designs in this literature fall into several categories: single-arm and comparative diagnostic accuracy studies in adults, a randomized crossover study against the insulin tolerance test, single-dose pharmacology studies in healthy volunteers, a dedicated cardiac repolarisation study, a pilot interventional trial in a disease population, and preclinical and translational work in epilepsy models.

Limits of the evidence in Module 1: the verified literature is dominated by diagnostic testing in adults. There is no body of long-term, repeated-administration human research here, and no studies of macimorelin used as a chronic therapy for body composition, athletic performance or ageing.

Module 2: Mechanism as described in the literature

The mechanism described across these papers is receptor-level rather than speculative. Macimorelin binds and activates the ghrelin receptor GHSR-1a on pituitary somatotrophs and hypothalamic neurons, mimicking the action of ghrelin and triggering a transient release of stored growth hormone; the resulting GH peak is what diagnostic testing measures (PMID 24834478). Because the receptor pathway is intact in healthy pituitary tissue but blunted when somatotroph reserve is impaired, the peak GH concentration after a weight-based oral dose was used as the discriminating variable in the validation study (PMID 23559086).

A 2025 structural pharmacology paper examined the molecular recognition of two approved drugs, macimorelin and anamorelin, by the growth hormone secretagogue receptor, describing how each ligand occupies the receptor binding pocket and how that engagement relates to receptor activation (PMID 40542284). That work provides the structural basis for the functional pharmacology observed clinically.

Mechanistic interest has not been confined to GH. Researchers gave oral macimorelin to healthy volunteers and measured copeptin alongside anterior pituitary hormones, asking whether GHSR activation influences axes beyond the somatotroph (PMID 33615399). A companion analysis pooled data from the Glucacop, Macicop and CARGO studies to examine how glucose dynamics interact with copeptin responses after glucagon, arginine and macimorelin stimulation in healthy adults (PMID 35723775).

In the neurological literature, macimorelin was investigated as a ghrelin receptor agonist with translational potential for seizure suppression in pharmacoresistant epilepsy, extending the mechanism from pituitary secretion to central nervous system excitability (PMID 34157194).

Limits of the evidence in Module 2: receptor binding and acute hormone release are well described, but mechanism does not equal clinical benefit. The structural work is molecular, the copeptin studies are single-dose volunteer pharmacology, and the epilepsy work is translational rather than a completed efficacy programme.

Module 3: Reported outcomes by study

Diagnostic accuracy in adults

The pivotal validation study of the macimorelin (AEZS-130)-stimulated GH test evaluated a novel oral stimulation test for the diagnosis of adult GH deficiency using a 0.5 mg/kg oral dose, and researchers reported sensitivity of 82% and specificity of 92% at a peak GH cut-point of 2.8 ng/mL (PMID 23559086). A review of the macimorelin-stimulated GH test placed those findings in the context of existing provocative tests and the practical difficulties of insulin-induced hypoglycaemia testing (PMID 24834478).

The 2018 study compared oral macimorelin with the insulin tolerance test in adults evaluated for GH deficiency, using agreement between the two tests as the primary endpoint, and researchers reported that the oral test showed high agreement with the reference test and was reproducible on repeat administration (PMID 29860473). A later analysis re-examined the sensitivity and specificity of the macimorelin test for diagnosis of AGHD in a clinical cohort, addressing how the test performs outside the conditions of a registration trial (PMID 33320108).

Other populations and endpoints

Limits of the evidence in Module 3: the strongest data are diagnostic, not therapeutic. Accuracy figures are cut-point dependent and derived from selected populations, the cachexia trial was explicitly a pilot, and the epilepsy work is not a completed clinical efficacy programme. None of these studies established that macimorelin improves any long-term health outcome.

Module 4: Macimorelin Side Effects: What Studies Report

Adverse events in this literature come from single-dose administration in diagnostic and volunteer settings, so the safety picture reflects acute exposure rather than repeated use.

• Taste disturbance. Dysgeusia — commonly described as a metallic or bitter taste — was the adverse event most consistently reported after oral macimorelin in the randomized comparison against the insulin tolerance test, where the study recorded treatment-emergent events for both tests (PMID 29860473), and it was also noted in the original validation study of the oral test (PMID 23559086).
• General tolerability. A single-dose, randomized controlled study in healthy adults assessed safety, tolerability, pharmacokinetics and pharmacodynamics and reported that macimorelin was generally well tolerated, with adverse events described as mild and transient (PMID 32325373).
• Cardiac repolarisation. A thorough QT/QTc study evaluated the effect of macimorelin on cardiac safety parameters in healthy participants, comparing therapeutic and supratherapeutic exposure, and researchers reported an effect on the QTc interval that is relevant to how the agent is labelled and monitored (PMID 32961034).
• Disease-population safety. The pilot clinical trial in patients with cancer cachexia was designed to assess safety as well as efficacy, and it reported safety findings in that more fragile population alongside its exploratory endpoints (PMID 36860137).
• Comparative safety framing. A review of the macimorelin-stimulated GH test discussed tolerability relative to insulin-induced hypoglycaemia testing, which carries its own risks in older patients and those with cardiovascular or seizure history (PMID 24834478).

Limits of the evidence in Module 4: adverse-event data here describe one-off, weight-based oral dosing in monitored settings. The literature does not describe adverse events from repeated dosing, does not quantify rare events, and does not establish safety in populations excluded from these trials, including pregnancy. Cardiac repolarisation findings in healthy volunteers cannot be extrapolated to people taking other QT-affecting medicines.

Module 5: Pharmacokinetics where data exist

The most direct pharmacokinetic data in this verified set come from a single-dose, randomized controlled study in healthy adults, in which researchers characterised the absorption and disposition of oral macimorelin together with its pharmacodynamic effect on growth hormone (PMID 32325373). The clinically important pharmacokinetic property is oral bioavailability: unlike injected or infused secretagogues, macimorelin was developed to produce a measurable GH response after an oral dose, which is the basis of the test described in the validation paper (PMID 23559086).

Pharmacodynamically, the GH response is transient, which is why diagnostic protocols rely on serial post-dose GH sampling rather than a single measurement; the randomized study against the insulin tolerance test used this serial sampling approach to define peak stimulated GH (PMID 29860473). Exposure–response considerations also underpinned the thorough QT/QTc study, which compared cardiac parameters at therapeutic and higher exposures in healthy participants (PMID 32961034). Physiological modifiers of the response have been examined too: the pooled Glucacop, Macicop and CARGO analysis looked at how glucose dynamics accompany stimulation testing with glucagon, arginine and macimorelin in healthy adults (PMID 35723775).

Limits of the evidence in Module 5: published pharmacokinetics are single-dose and largely in healthy adults. Accumulation, steady-state behaviour, and pharmacokinetics in hepatic or renal impairment are not described in this verified set, and the literature here does not characterise food effects, drug–drug interaction magnitudes or paediatric pharmacokinetics in detail.

Module 6: Regulatory status

Macimorelin is an approved prescription medicine, not a research chemical in its diagnostic form. It is marketed as an oral solution for the diagnosis of adult growth hormone deficiency, and the review literature on childhood-onset GH deficiency describes macimorelin acetate explicitly as an approved diagnostic agent whose use in paediatric populations has been the subject of further study (PMID 36694890). Its regulatory indication is diagnostic: the approved use is to provoke and measure a GH response, not to treat GH deficiency, which remains the role of recombinant growth hormone.

Several points of status are worth stating plainly:

1. Approved product. The approved indication covers diagnostic stimulation testing in adults, performed under medical supervision with laboratory GH measurement, as reflected in the design of the registration-supporting comparison with the insulin tolerance test (PMID 29860473).
2. Research-use-only material. Substances labelled macimorelin and sold for laboratory research are designated research use only. Research-use-only labelling means a material has not been manufactured, tested or released for human administration, and it is not an approved drug regardless of chemical name.
3. Compounding. In the United States, compounding of a drug that is essentially a copy of a commercially available approved product is restricted under federal law, and macimorelin is not among the bulk substances routinely used in traditional peptide compounding. Regulatory categories differ by country and change over time.
4. Paediatric status. Extension of the test to childhood-onset GH deficiency has been discussed in the review literature rather than settled by a single definitive trial (PMID 36694890).

This section is informational and is not legal advice; regulatory classification depends on jurisdiction and should be confirmed with current agency sources or qualified counsel.

Limits of the evidence in Module 6: approval status is not a statement about benefit outside the approved indication. An approved diagnostic agent has been reviewed for use as a diagnostic agent, and nothing in that approval speaks to unapproved uses, unsupervised use, or use of non-pharmaceutical material.

What the studies did not test

Reading across the verified literature, several gaps are as informative as the findings:

• Chronic administration. No study in this set evaluated repeated or long-term macimorelin dosing in healthy people; the diagnostic studies used single weight-based oral doses (PMID 23559086).
• Body composition, strength or ageing endpoints. None of these papers measured lean mass, fat mass, strength or recovery as outcomes of macimorelin administration.
• Sleep, appetite or wellbeing as primary outcomes in healthy adults. The healthy-volunteer work measured hormone responses and safety parameters rather than subjective outcomes (PMID 33615399, PMID 32325373).
• Definitive therapeutic efficacy. The cachexia trial was a pilot, and the epilepsy work was translational; neither constitutes a completed phase 3 efficacy programme (PMID 36860137, PMID 34157194).
• Head-to-head safety against other secretagogues in patients. The structural comparison with anamorelin was molecular, not clinical (PMID 40542284).

Readers reviewing this literature should treat macimorelin as what the evidence describes: an oral ghrelin receptor agonist validated as a diagnostic stimulation test, with a limited exploratory literature elsewhere. Questions about testing, results interpretation or any medical condition belong with a licensed physician.

References

• Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency (The Journal of Clinical Endocrinology and Metabolism, 2013)
• The macimorelin-stimulated growth hormone test for adult growth hormone deficiency diagnosis (Expert Review of Molecular Diagnostics, 2014)
• Macimorelin as a Diagnostic Test for Adult GH Deficiency (The Journal of Clinical Endocrinology and Metabolism, 2018)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study (Growth Hormone & IGF Research, 2020)
• Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants (Clinical Pharmacology in Drug Development, 2021)
• Sensitivity and specificity of the macimorelin test for diagnosis of AGHD (Endocrine Connections, 2021)
• Effects of oral macimorelin on copeptin and anterior pituitary hormones in healthy volunteers (Pituitary, 2021)
• Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy (European Journal of Neurology, 2021)
• The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults (Pituitary, 2022)
• Macimorelin Acetate for the Diagnosis of Childhood-onset Growth Hormone Deficiency (touchREVIEWS in Endocrinology, 2022)
• Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia (Journal of Cachexia, Sarcopenia and Muscle, 2023)
• Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor (Acta Pharmacologica Sinica, 2025)